Abstract
Propafenone is a potent antiarrhythmic agent with a strong membrane-stabilizing effect (Fill et al. 1977; Zeiler et al. 1981) which has been commercially available in Europe since 1977 under the trade name Rytmonorm. Clinical studies have indicated effectiveness in suppressing chronic recurrent supraventricular and ventricular tachyarrhythmias and ectopic beats (Aldor and Haeger 1977; Baedeker et al. 1977; Harlin 1976; Koch 1977).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aldor E, Haeger H, (1977) Clinical experiences with propafenone. Drug Dev Eval 1: 115–119
Baedeker W, Wirtzfeld A, Sack D, (1977) The antiarrhythmic effect of propafenone in ventricular tachycardias. Herz/Kreisl 9: 348–352
Fill WD, Kuehn P, Probst P, (1977) Use of propafenone in man. Clinical results on the effects on electrophysiological and hemodynamic parameters. Drug Dev Eval 1: 71–79
Harlin M, (1976) Propafenone in therapy-resistant arrhythmias. Medical Tribune 2: 40–41
Koch R, (1977) Action of propafenone in ventricular arrhythmia. Drug Dev Eval 1: 84–89
Zeiler RH, Gough WB, Sung R, (1981) Electrophysiologic effects of propafenone on canine ischémic cardiac cells. Am J Cardiol 47: 483
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
deSoyza, N., Murphy, M., Sakhaii, M., Treat, L. (1983). The Safety and Efficacy of Propafenone in Suppressing Ventricular Ectopy. In: Schlepper, M., Olsson, B. (eds) Cardiac Arrhythmias. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-68926-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-68926-0_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-68928-4
Online ISBN: 978-3-642-68926-0
eBook Packages: Springer Book Archive